… work; (2) IR has received research support from and acted as a consultant for Fonterra that
might have an interest in the submitted work in the previous 3 years; JB, IR, AA and GM had …

This work provides a systematic review of the literature from January 2003 to April 2014
pertaining to the incidence, pathophysiology, diagnosis, and treatment of osteonecrosis of the …

… Mark J Bolland, senior research fellow,1 Andrew Grey, associate professor,1 Alison
Avenell, clinical research fellow,2 Greg D Gamble, research fellow,1 Ian R Reid, professor of …

Background Denosumab is a fully human monoclonal antibody to the receptor activator of
nuclear factor-κB ligand (RANKL) that blocks its binding to RANK, inhibiting the development …

Background A single infusion of intravenous zoledronic acid decreases bone turnover and
improves bone density at 12 months in postmenopausal women with osteoporosis. We …

Background Bisphosphonates are effective agents for the management of osteoporosis.
Their low bioavailability and low potency necessitate frequent administration on an empty …

Objective To determine the effect of calcium supplementation on myocardial infarction,
stroke, and sudden death in healthy postmenopausal women. Design Randomised, placebo …

… In men in this study, lean mass was related to BMD, but not to BMAD, consistent with the
data of Reid et al. cited previously. In their study of postmenopausal women, Riis et al. found …

Zoledronic acid 5 mg (ZOL) annually for 3 years reduces fracture risk in postmenopausal
women with osteoporosis. To investigate long‐term effects of ZOL on bone mineral density (…

Background Findings from recent meta-analyses of vitamin D supplementation without co-administration
of calcium have not shown fracture prevention, possibly because of insufficient …